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ABSTRACT 
AIM: To evaluate the clinical features, fundus fluorescein angiographic (FFA), optical 
coherence tomographic  (OCT)  findings  and  to study the effect of intravitreal bevacizumab 
in type 2 parafoveal telangiectasia (PFT). 
PATIENTS AND METHODS: In this prospective, interventional case series, patients with 
clinical diagnosis of PFT were divided into 3 groups: eyes with PFT alone (group 1), eyes 
with PFT with cystoid macular edema (CME) (group 2) and eyes with PFT with Choroidal 
neovascular membrane (CNVM) (group 3). Eyes with PFT with CME and CNVM received 
intravitreal bevacizumab (2.5mg/0.1ml). Main outcome measures studied were reduction in 
macular thickness and improvement in visual acuity.  
RESULTS: Eighty eyes of forty patients (14 males and 26 females), ranging in age from 40 
to 70 were included in the study. Eyes with PFT alone showed no change in visual acuity or 
macular thickness during follow up. Eyes with PFT with CME showed improvement in visual 
acuity (p<0.001) and in macular thickness (p<0.001). Eyes with PFT with CNVM showed 
improvement in macular thickness after bevacizumab (p<0.001) but not in visual acuity. 
 
CONCLUSION: Intravitreal bevacizumab is effective in management of eyes with PFT with 
CME. In eyes with PFT with CNV, there may be not be improvement in vision after 
bevacizumab despite reduction in macular thickness. 
  
Key words: Bevacizumab, Cystoid macular edema, Choroidal neovascular membrane,  
Parafoveal telengectasia 
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INTRODUCTION 
 
 The term “retinal telangiectasis” was first used by Reese to describe the 
developmental vascular anomalies seen in patients with Coats’ disease and Leber’s 
miliary aneurysms.¹ The telangiectatic vessels are characterized by localised, congenital 
abnormal segments of blood vessels that result in leakage. The telangiectasis may be 
localised only to the capillaries of the parafoveal region, known as Parafoveal 
Telangiectasis, and is characterized by the microaneurysmal and saccular dilation and 
capillary nonperfusion of the parafoveal capillaries. The more generalised form is 
known as Coats’ disease and is characterized by the telangiectatic retinal vessels that 
cause massive subretinal and intraretinal exudation. 
 
 Parafoveal telangiectasis was first described by Gass who observed that the 
parafoveal retinal capillaries only showed telangiectasia; fluorescein angiography was 
required to diagnose this cases.² since the capillaries affected are confined to the 
juxtafoveal region. Telangiectasis of parafoveal capillaries could either be idiopathic or 
secondary to a number of retinal vascular disorders or systemic diseases. The idiopathic 
form further could be either (a) developmental which is usually seen unilaterally in 
males (spectrum of Coats’ disease); or (b) acquired which tends to present bilaterally 
without any gender predilection. These are further subdivided according to the revised 
classification of Gass and Blodi.³ Type 2 parafoveal telangiectasia is the form most 
commonly encountered. 
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Parafoveal Telangiectasis is classified ³ as:  
• Group1A - Unilateral congenital juxtafoveal telangiectasis;  
• Group1B - Unilateral idiopathic juxtafoveal telangiectasis; 
• Group 2A - Adult, bilateral, idiopathic, acquired juxtafoveal telangiectasis; 
• Group 2B - Juvenile ,occult, familial, idiopathic, juxtafoveal telangiectasis; 
• Group 3A – Occlusive, idiopathic, juxtafoveal retinal telangiectasis; and 
• Group 3B – Occlusive, idiopathic, juxtafoveal retinal telangiectasis associated with 
central nervous system vasculopathy. 
 
 Patients typically present in the fifth and sixth decades of life with mild blurring 
of vision in one or both eyes which may progress, primarily from foveolar atrophy or 
subretinal neovascularization.4 Biomicroscopy reveals symmetric blunting of the foveal 
reflex with a mild grayish appearance of the parafoveal retina, minimal serous 
exudation, and no lipid deposition.4,5 In addition, glistening white or yellow-white 
crystalline deposits may be noted in the superficial parafoveal retina in approximately 
40% of patients.6 In some patients, a small, yellow lesion, 1/3 disk diameter in size, 
develops within the foveal avascular zone and appears to represent an inner retinal 
cavitation on evaluation by optical coherence tomography (OCT). 4,5 
 
Histopathology 
 The histopathological features of IJFT IIA have been described. In a landmark 
histopathological report, Green et al.7 did not find telangiectasis of the retinal vessels 
but, instead, thickening of retinal capillaries from marked proliferation of the basement 
membrane in a multilayered configuration, and narrowing of the caliber of the lumen. 
Degeneration of pericytes, and occasionally endothelial cells, was also described, not 
only in the affected juxtafoveal area, but also to a lesser degree throughout the retina. 
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Cellular debris from degenerated endothelial cells and pericytes, and multimembranous 
lamellar lipid were entrapped between layers of capillary basement membrane. 
Localized endothelial defects in the temporal parafoveal area were seen, and the 
authors postulated that these were the sites at which fluorescein diffused into walls and 
became trapped by the thickened capillary wall. Intracellular and extracellular edema, 
especially prominent in the inner retinal layers was observed. Retinal capillary 
proliferation into the outer retina as far as the photoreceptor layer was also noted.7 
 
 Another histopathological report of a more advanced case with SRNV 
corroborated these findings and demonstrated in addition (1) dilation and proliferation 
of retinal capillaries into the outer retinal layers and into the subretinal space with 
retinochoroidal vascular anastomosis and (2) intraretinal migration of the RPE along 
the course of the telangiectatic vessels.8 
 
 All these histological features corroborate the clinical findings described by 
Gass et al., and although they suggest that the juxtafoveal retinal capillaries are the 
primary tissues involved in this condition, 10,11,12 they also support what Gass has 
postulated, i.e., that capillary dilation and “telangiectasis” does not occur until later in 
the process.9 
 
Pathophysiology 
 The precise pathogenesis of IJFT IIA is controversial. In their earlier report and 
based on the angiographic findings, Gass and associates initially proposed a primary 
role of the retinal capillaries.13 The altered capillary wall associated with metabolic 
alterations and increased endothelial permeability, incite chronic nutritional damage to 
the retina, particularly the Müller cells.14 Further changes in the outer capillary bed 
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would cause an alteration in the pattern of venous outflow and the formation of right-
angled venules. The nutritional deprivation of the middle retinal layers would lead to 
degeneration and atrophy of the outer retina including the photoreceptors which would 
cause the gradual visual loss and permit subretinal and intraretinal pigment epithelial 
migration and proliferation to form black plaques in the vicinity of the right-angled 
venules. Photoreceptor atrophy would also permit the proliferating capillaries to invade 
the subretinal space causing SRNV and the latter may develop anastomosis with the 
choroidal vessels.10,11,15 In later years however, Gass commented that IJFT IIA “is not 
primarily a leaky retinal blood vessel disease,” but rather “the primary abnormality may 
reside in one or both of the parafoveolar retinal neural or Müller cells” since he 
observed that telangiectatic capillary dilation does not occur until later in the process, 
and the loss of central vision is due to photoreceptors atrophy in the absence of macular 
edema.9,14 
 
 Although, the clinical pathologic report by Green et al.12 showed intracellular and 
intercellular edema primarily in the inner retinal layers as well as capillary endothelial 
cell degeneration and regeneration, the unusual capillary endothelial abnormalities 
observed could, in fact, be secondary to Müller cell dysfunction. Müller cells in the 
retina, like astrocytes in the brain, are critical to proper function of the retinal capillary 
endothelium and the health of the surrounding neurons.16–19 A primary degeneration or 
dysfunction of the parafoveolar Müller cells, could lead in this scenario to (1) retinal 
endothelial cell degeneration as suggested by Gass and Yannuzzi,14,20 or accelerated 
rate of cell death and replacement as suggested by Green12 as a possible triggering 
mechanism for proliferation of retinal capillaries; and (2) retinal thinning, accompanied 
later by a breakdown of the blood–retinal barrier at the parafoveolar retinal capillaries, 
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causing a superimposed limited edema. The precise mechanism for the retinal capillary 
proliferation, however, remains unknown. 
 
 Superficial crystalline deposits are a common finding in IJFT IIA and are 
thought to represent the remnants of degenerated Müller cells because of their location 
near the internal limiting membrane (ILM).15 The process of subretinal proliferation is 
similar to the neovascular form of age-related macular degeneration known as retinal 
angiomatous proliferation (RAP).21 Both IJFT IIA and RAP can be associated with 
retino-retinal anastomoses that may extend beneath the retina when SRNV occurs 22,23 
and plaques of subretinal pigmentation.24 The latter are hypothesized to represent 
reactive hyperplasia of the RPE induced by extension of the retinal vascular 
proliferation posteriorly toward it.20 
 
 Initially, telangiectasis is not visible on biomicroscopy, and fluorescein 
angiography shows only mild staining within one disk diameter of the foveola, 
especially temporally. With progression, these eyes may develop dilated right-angled 
retinal venules and arterioles, and stellate plaques of retinal pigment hyperplasia, as 
well as intra-and subretinal anastomosis and subretinal neovascularisation occur.25,26,27  
Loss of central visual acuity may be rapid, and 81% of untreated eyes have a final 
acuity of 20/200 or worse.  
 
 The grid laser is not indicated for treatment of type 2 parafoveal telangiectasis 
because it does not improve or stabilize long-term visual acuity28. In addition, use of 
laser may lead to the development of subretinal hemorrhage 29 and choroidal 
neovascularization.28 A variety of therapeutic modalities have been employed to treat 
subretinal neovascularization complicating this disorder. Photo-dynamic therapy30,31 
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and transpupillary thermotherapy32,33 have demonstrated efficacy; however, the 
subretinal neovascularization in idiopathic juxtafoveal retinal telangiectasis arises from 
the retina, as opposed to the choroid, and activation of photosensitizing dye in the 
retinal layers may cause iatrogenic damage.30,33 Laser photocoagulation may help 
stabilize central visual acuity but induces an iatrogenic scotoma,34 submacular surgery 
has demonstrated poor outcomes. 35 Anti-VEGF drugs hold promise for treating 
neovascularization associated with CNVM. The role of bevacizumab in the treatment 
of parafoveal telengectasia without CNVM is less clear. 
 
  
P a g e  | 7 
 
AIM OF THE STUDY 
 
a) To document the clinical features, fundus fluorescein angiographic (FFA) and 
optical coherence tomographic (OCT) findings in patients presenting with type 
2 parafoveal telangiectasia at a tertiary eye care facility. 
b) To evaluate the effect of intravitreal bevacizumab in treatment of type 2 
parafoveal telangiectasia. 
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REVIEW OF LITERATURE 
 
 Matsumoto et al. 36 investigated the efficacy of intravitreal bevacizumab for the 
treatment of idiopathic macular telangiectasia (IMT). Ten eyes of eight consecutive 
patients with IMT were studied. All patients were treated with intravitreal bevacizumab 
(1.25 mg) injections at baseline. There were no changes in the mean visual acuity in 
either eye in any of the patients. These authors concluded that Type 2 IMT improved 
anatomically with bevacizumab treatment, despite a lack of improvement in vision, and 
bevacizumab effectively decreased vascular permeability and retinal edema in the short 
term. 
 
 Gamulescu et al.37 described functional and morphological long-term follow-up 
results in patients with IMT treated with intravitreal bevacizumab. This was a 
retrospective case series of three consecutive male patients with IMT who were treated 
with intravitreal bevacizumab injections. A single intravitreal bevacizumab injection 
resulted in a marked improvement in best corrected visual acuity (BCVA) from 20/50 
to 20/20 than the patient with type 1 (aneurysmal) IMT during the first 4 weeks. These 
authors concluded that patients with type 1 IMT with pronounced macular oedema on 
OCT may benefit from intravitreal bevacizumab injections, showing functional as well 
as morphological improvement, while patients with type 2 IMT with minimal cystic 
changes on OCT do not show functional improvement despite repeated injections. 
 
 Issa et al.38 reported on the short-term effects of intravitreal bevacizumab in 
patients with type 2 IMT in a non-comparative, interventional, retrospective case series. 
Seven eyes of six patients with type 2 IMT were evaluated. Patients received 2 doses of 
intravitreal bevacizumab (1.5 mg) at a 4-week interval. A significant increase in mean 
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VA of 8 ETDRS letters at 8 weeks was found. Visual acuity improved by more than 15 
letters in one patient and by 10 to 15 letters in two patients and remained stable (to +10 
letters) in another four patients, compared with baseline. All patients showed a 
reduction in extension and intensity of late-stage parafoveal hyperfluorescence on 
fluorescein angiography. In OCT imaging, mean retinal thickness showed a significant 
reduction in the foveal and in the parafoveal zones. The most pronounced effect (mean 
decrease, 22Î¼m) was in the parafoveal temporal zone. No significant ocular or 
systemic side-effects were observed. These authors concluded, based on their short-
term results, that inhibition of vascular endothelial growth factor (VEGF) by 
intravitreal bevacizumab is associated with a decrease in retinal thickness and a 
reduction in angiographic leakage in type 2 IMT; they also opined that intravitreal 
bevacizumab may improve VA in affected patients. 
 
 Kovach et al.39 sought to determine whether inhibition of VEGF-A affects 
visual acuity, fluorescein angiographic, and OCT outcomes in patients with perifoveal 
telangiectasia (PT)/ (synonyms are macular telangiectasia, Type 2 juxtafoveolar retinal 
telangiectasis group 2A). In this retrospective review of patients with PT treated with 
intravitreal bevacizumab at the Bascom Palmer Eye Institute, in Florida (USA), best-
corrected visual acuity, fluorescein angiography, and OCT measurements were 
performed on nine eyes of eight patients. Five eyes had proliferative PT, characterized 
by subretinal neovascularization involving the macula. After treatment (follow-up 
ranged from 4 to 27 months) the mean BCVA remained stable for the four eyes with 
nonproliferative PT, whereas in the five eyes with proliferative PT, BCVA was 
unchanged or improved after treatment. All eyes demonstrated decreased intraretinal 
leakage on fluorescein angiography after an injection of bevacizumab, and eyes with 
proliferative PT showed decreased growth and leakage of the subretinal 
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neovascularization. The mean decrease in OCT central retinal thickness was less than 
30 μ. These investigators were of the opinion that in nonproliferative PT, intravitreal 
bevacizumab decreases fluorescein angiographic leakage without any short-term effect 
on visual acuity or OCT appearance whereas in proliferative PT, intravitreal 
bevacizumab arrests the leakage and growth of subretinal neovascularization with the 
possibility of visual acuity improvement. 
 
 Moon et al.40 assessed the potential visual benefit of intravitreal bevacizumab in 
a patient with idiopathic juxtafoveal retinal telangiectasis refractory to focal laser 
treatment; an intravitreal injection of bevacizumab (1.25 mg) was given. Within 1 
week, visual acuity improved from 20/50 to 20/25 and OCT demonstrated complete 
resolution of macular edema without any adverse effect due to the injection. The 
macular edema recurred after 3 months, requiring a repeat injection of bevacizumab, 
with subsequent resolution of macular edema. These authors believed that an 
intravitreal injection of bevacizumab may provide potential short-term visual benefit in 
patients with macular edema from idiopathic juxtafoveal retinal telangiectasis. 
 
 Idiopathic perifoveal telangiectasia (IPT) is a disorder characterized by focal 
parafoveal capillary dilatation of unknown cause. Photodynamic therapy (PDT) is 
reported to be efficacious in the treatment of subretinal neovascularization (SRN) 
associated with idiopathic juxtafoveal retinal telangiectasis; however, visual 
improvement is limited. Cakir et al.41 described the clinical, angiographic, and OCT 
findings for a patient with IPT complicated by SRN who underwent treatment with 
PDT and bevacizumab. The patient underwent two sessions of PDT; however, 
metamorphopsia persisted, and visual acuity further decreased to 20/100 after the 
second PDT. Hence, after PDT, two injections of intravitreal bevacizumab (1.25 mg) 
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were administered, following which visual acuity increased dramatically from 20/100 
to 20/25. Four months after the second injection, there was no recurrence, and the 
patient was asymptomatic. These authors concluded that intravitreal bevacizumab 
treatment should be considered for patients with SRN associated with perifoveal 
telangiectasis, especially after insufficient therapeutic response to PDT. 
   
 Mandal et al.42, in a nonrandomised interventional case series, evaluated the 
efficacy and safety of intravitreal bevacizumab in the treatment of SRN secondary to 
type 2A idiopathic juxtafoveal telangiectasia (IJT). Intravitreal bevacizumab (1.25 
mg/0.05 ml) was injected as primary treatment into six eyes of six patients with SRN 
due to IJT. OCT and fundus fluorescein angiography (FFA) findings were examined 
before and after treatment (the patients were followed up for 3-6 months). Pre-injection 
BCVA measured from 20/400 to 20/120 (mean 20/200). After a mean follow-up of 4.2 
months, post-injection BCVA measured from 20/200 to 20/50 (mean 20/100). At the 
last visit, BCVA was found to have improved by two or more lines in five eyes (83%) 
and remained the same in one eye (17%). The mean central foveal thickness improved 
from 263 µ (range, 165 to 393 µ) to 201 µ (range, 126 to 351 µ), representing an 
average reduction of 62. Only one eye received more than one two bevacizumab 
injections and no significant complications were observed. These authors concluded 
that in their small series, intravitreal bevacizumab appeared to be a safe and effective 
treatment for SRN secondary to type 2A IJT. 
 
 Charbel et al.43 evaluated retrospectively the effects of intravitreal bevacizumab 
for non-proliferative type 2 idiopathic macular telangiectasia (type 2 IMT) for a mean 
follow-up of 18 months. Six eyes of five patients with type 2 IMT received two doses 
of intravitreal bevacizumab (1.5mg) at a 4 week interval. All patients underwent visual 
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acuity testing, slit lamp biomicroscopy, fluorescein angiography, and retinal thickness 
analysis by optical coherence tomography and fundus-controlled micro-perimetry. The 
mean VA increased significantly, Parafoveal leakage in FFA and mean central retinal 
thickness was decreased in all eyes following treatment. A rebound effect was observed 
after 3-4 months, and at the last visit, retinal thickness was increased in selected retinal 
sectors including the fellow eye. Inhibition of vascular endothelial growth factor 
(VEGF) by intravitreal bevacizumab may lead to functional improvement as well as 
transient decrease in leakage and retinal thickness in patients with type 2 IMT.  
 
 Initially, telangiectasis is not visible on biomicroscopy, and FFA shows only 
mild staining within one disk diameter of the foveola, especially temporally. With 
progression, these eyes may develop dilated right-angled retinal venules and arterioles 
and stellate plaques of retinal pigment epithelial hyperplasia, as well as intra- and 
subretinal anastomosis and subretinal neovascularization.  The typical FFA features 
include dilated, ectatic parafoveal capillaries; these incompetent vessels display 
hyperfluorescence, hyperplasia of the retinal pigment epithelium (RPE) routinely block 
fluorescence.  
 
 Optical coherence tomography (OCT) is a new diagnostic imaging technology. 
The basic principle of OCT is that low  coherence  light  is  directed  onto  a  beam 
splitter,  resulting  in  2  beams,  one  directed  at  the  tissue  of  interest  ( signal  beam 
)  and  the  other  at  a  reference mirror ( reference  beam  ).  The  amplitude  and  delay 
of  tissue  reflection  is  determined  by  an  interferometer  that  adds  the 
electromagnetic  waves  in  the  2  reflected light  beams. Because  of  the  low 
coherence  of  the  light  source,  interference  of  light  reflected  from  the  signal  and 
reference  beams  only  occurs  when  the  delay  of  the  reflections  is  almost 
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matched, resulting  in  high  resolution. Axial  resolution  of  the  OCT  system  is 
determined  by  the  coherence  length  of the  source.  The super luminescent diode 
source  has  a  bandwidth  of  30nm,  with  a  full-width  half  maximum  ranging 
resolution  of  14  microns  in  air.  After  adjusting for  the  index  of  refraction  of  the 
eye,  the  full-width  half-maximum  ranging resolution  is  10  microns.  The  lateral 
image  resolution  is  a  function  of  the beam  waist  diameter  in  the  sample  could 
be  made  as  small  as  a  few  tens  of micrometers. This high resolution permits 
tomographic imaging of tissue microstructure 
 
 The OCT software provides a variety of retinal scanning protocols including 
linear, circular, radial and parallel line scans. The duration can be shortened by 
performing three fast scans, and then averaging them to give the final interpretation. 
The scan can be adjusted manually or automatically with the position of the signal. The 
signal strength can be optimised automatically by pressing z-axis offset and 
polarisation ‘buttons’. The images are continuously displayed on the monitor, and can 
be freezed whenever necessary. All the frozen scan images (upto 8) can be reviewed 
and image of the best quality can be saved. If none of the scans is good, the scanning 
process can be repeated. 
 
 Following the scanning phase, the appropriate scan analysis protocol can be 
used. There are different scan analysis protocols which allow quantitative analysis of 
the scan. The scan image can be qualitatively analysed. For qualitative analysis, 
individual scan images can be studied and interpreted in detail. The alignment 
algorithm reduces artefacts caused by axial movement of the eye during scan. The 
normal algorithm allows comparison of scans with varying signals. The OCT machine 
has Gaussian smoothing, proportional elevation and profile algorithm scan for 
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refinement of the scan image. Applying of grey scale image allows detection of various 
minute differences in the contrast sensitivity. A database is also available in the latest 
software for comparison of peripapillary retinal nerve fibre layer and macular 
thickness. Each  eye  of each  subject  was  dilated  with  1%  tropicamide  and  2-5% 
phenylephrine   hydrochloride  before  recording  the  image. The patient was seated 
comfortably in front of the OCT machine with chin positioned on the chin rest, and is 
asked to fixate on the fixation target. The internal fixation (green colour light) target 
was the commonly used fixation target. After fixation, the operator selected the desired 
scan and aligned the instrument so that the fundus image and scan beam were displayed 
on the screen. In patients with significant refractive errors, rotation of the dioptre 
compensation device was found to improve image quality. Ranging measurements 
were  performed  using  a  fibro-optically  integrated  Michelson interferometer  with  a 
short-coherence  length  super luminescent  diode  source.  The system  used  for  this 
study  used  new  data  analysis  software  to  quantitate nerve fibre layer (NFL) and 
retinal  thickness. Retinal  thickness  was  quantitated  by the computer  for  each  scan 
in  the  image  as  the distance  between   the  first  reflection  at  the  vitreoretinal  
interface  and  the  anterior boundary  of  the  red,  reflective  layer  corresponding  to 
the  retinal  pigment epithelium  and  choriocapillaries.   
 
 Specific scanning protocols in OCT include retinal scanning and macular 
scanning protocols. Retinal scanning protocols include line scans, radial lines, raster 
lines, cross hair, X-line and circle. 
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SCAN TECHNICAL SPECIFICATIONS UTILITY 
Line 
Default length:5mm 
Default angle:0◦ 
Nasal position is zero position. 
Defaults can be altered as needed. 
Multiple line scans can be 
obtained by changing default 
angle/length without returning to 
main window. 
Radial lines 
Default number:6 lines. 
(30◦ separation) 
Default length of each line:6mm.(this 
can be altered) 
Defaults can be altered as needed (± 
24lines) 
For determining entire macular 
thickness/volume. 
Raster lines 
Multiple equidistant parallel lines are 
used to scan a square area. 
Default setting scans a 3mm square 
area using six lines. 
Lines scan from superior to inferior 
and nasal to temporal. 
Defaults can be altered as needed (± 
24lines) 
By altering defaults an entire 
area of pathology can be 
scanned. 
Repeat scan 
Fixes defaults (size, angle, fixation 
LED and landmark) automatically to 
that used in an earlier selected scan. 
Monitoring change during 
follow up visits. 
Macular 
thickness 
 Default number:6 lines.(30◦ 
separation) 
Default length of each line:6mm.(this 
cannot be altered) 
Defaults can be altered as needed  
(± 24lines) 
For determining entire macular 
thickness/volume. 
Fast macular 
thickness 
Obtains six scans of 6mm length 
rapidly (within ± 2seconds) 
Defaults cannot be altered. 
Allows comparative 
thickness/volume analysis. 
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 Macular scanning protocols include macular thickness scan, fast macular 
thickness, raster lines, and single line scan. Macular thickness map scan and fast 
macular thickness map are the two commonly used protocols. These protocols consist 
of radial scan length of 6mm at equally spaced angular (30◦) orientation. 
 
 Measurement of retinal thickness at selected points on the tomographs is 
obtained automatically by means of a computer algorithm, which assumes that the first 
highly reflective band corresponds to the vitreoretinal interface and the second 
corresponds to the retinal pigment epithelium. Thus, evaluating the displacement 
between anterior surfaces of these two interfaces determines retinal thickness. 
 
 Optical coherence tomography can demonstrate hyporeflective intraretinal 
cavitation without foveolar thickening and middle or inner layer hyperreflectivity 
corresponding to areas of retinal pigment epithelial migration.  
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PATIENTS AND METHODS 
 
 This prospective interventional study was done at Retina Clinic, Institute of 
Ophthalmology, Joseph Eye Hospital, Tiruchirapalli from April 2010 to August 2011. 
 
INCLUSION CRITERIA  
 Inclusion criteria included the following: 
 Patients with clinical diagnosis of PFT Type 2  
 Media clarity adequate to perform FFA and OCT 
 Follow up of at least 3 months 
 
EXCLUSION CRITERIA 
 Exclusion criteria included the following: 
 Patients with other retinal pathology affecting visual acuity 
 Patients with hazy media where FFA and OCT could not be performed 
 Patients who did not complete follow up for three months 
 
PROCEDURE 
 All patients underwent a complete ophthalmic examination which included  best 
corrected visual acuity (BCVA), intraocular pressure (IOP), slit lamp examination, 
fundus examination, fundus photography, fundus fluorescein angiography(FFA), optical 
coherence tomography (OCT) (fast macular scan using Zeiss Stratus 3 OCT). 
 
 Eighty eyes of forty patients (14 males and 26 females), ranging in age from 40 
to 70 were included in the study.  All patients were first informed of the procedure, and 
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the possible complications and informed written consent was obtained. The 
Institutional Ethics Committee (Institutional Review Board) approved the study. 
 
 Patients included in the study were divided into three groups for follow-up and 
treatment. 
• Group 1: eyes with PFT treated conservatively  
• Group 2: eyes with PFT and CME receiving intravitreal bevacizumab 
• Group 3: eyes with PFT and CNVM receiving intravitreal bevacizumab 
 
 All patients were followed up at 1 week, 1 month and 3 months after initial 
examination or intervention.  
 
The parameters checked after intervention included: 
1.  Measurement of BCVA  
2.  Slit-lamp examination 
3.  Fundus examination and photography 
4.  Measurement of IOP 
5.  OCT. 
 
 Main outcome measures studied were changes in clinical picture, OCT picture 
and visual acuity. 
 
INTRA VITREAL BEVACIZUMAB  
 Under aseptic precautions, after instillation of xylocaine (4%) drops, intravitreal 
bevacizumab (2.5 mg in 0.1 ml) was given. The site of injection was 4mm from the 
limbus in the inferotemporal quadrant. After the procedure, subconjunctival antibiotics 
were given and the patient was advised to take acetazolamide tablets and topical 
antibiotic drops.  
 BEVACIZU
 
FIGURE 1 
MAB INJECTED INTO THE EYE 
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 FIGURE 3 
OCT APPEARANCE OF PARAFOVEAL TELANGIECTASIA 
WITH CYSTIOD MACULAR EDEMA 
 
 
 FIGURE 4 
OCT APPEARANCE OF PARAFOVEAL TELANGIECTASIA 
WITH CHOROIDAL NEOVASCULAR MEMBERANE 
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RESULTS 
 
 Eighty eyes of forty patients were enrolled in the study. Of these 40 patients, 
fourteen were males (35%) and twenty-six were females (65%) (Figure 5). The patients 
ranged in age from 40 to 70 years. (Mean age: 54.16 ± [standard deviation {SD}] 8.25 
years). Fifteen patients were between 40 to 50 years of age, 14 patients were between 
51 to 60 years of age and 11 patients were between 61 to 70 years of age (Figure 6), 
(Table 1). 
 
 All the 40 patients enrolled in the study suffered from bilateral parafoveal 
telangiectasis. They were divided into three groups: 
 
Group 1: This group included patients with PFT who were under observation and 
treated conservatively. Out of 15 patients in this group, three were males and 12 were 
females. The age distribution ranged between 40 and 69 years (mean age 52.73 ± 9.05 
years). Five patients had both diabetes mellitus (DM) and hypertension (HTN) as 
associated systemic illnesses whereas one patient had both DM and ischemic heart 
disease (IHD) and five patients had only DM.  
 
 Details about the pre-treatment and post-treatment best corrected visual acuity 
(BCVA) and macular thickness in each individual eye in this group are shown in Fig. 
8a and Fig. 8b, respectively.  The mean BCVA at presentation was 0.264 ± 0.14 
decimals, which was identical to the mean vision (0.264 ± 0.14 decimals) after the three 
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month follow-up period. The mean macular thickness at presentation was 205.8 ± 56.32 
µ which also showed no change after the three month follow-up period. 
  
Group 2: This group included 14 patients with PFT and cystoid macular oedema who 
were treated with an intravitreal injection bevacizumab (0.1) ml under aseptic 
conditions.  Out of 14 patients, five were males and nine were females. The age 
distribution ranged from 40 to 65 years (mean age 54.0 ± 7.18 years). Four patients had 
DM and HTN as associated systemic illnesses, whereas two patients had only HTN and 
two patients had only DM and one patient had bronchial asthma.  
 
 Details about the pre-treatment and post-treatment BCVA and macular 
thickness values in each individual eye in this group are shown in Figs. 9 a and 11 a 
and Figs. 9b and 11b, respectively. The mean BCVA at presentation was 0.19 
(approximately 6/18) ± 0.1 decimals which, after injection of bevacizumab, showed a 
significant improvement to 0.26 (6/12) ± 0.096 decimals (`t’ test [degree of freedom 
{d.f.}= 42] = 2.13; P= 0.04) (Figure 13a). The mean macular thickness at presentation 
was 360.73 ± 43.2 µ which, when compared to the post-bevacizumab macular 
thickness, showed a significant decrease to 253.45 ± 42.6 µ (‘t’ test [d.f. = 42] = 8.3; 
P<0.0001) (Figure 13b). None of the patients exhibited decreased BCVA after 
intravitreal injection of bevacizumab. Six eyes did not show any change in visual 
acuity, but showed a significant reduction in macular thickness. 
 
Group 3: This group included 11 patients with PFT with choroidal neovascular 
membrane (CNVM) who were treated with an intravitreal injection of bevacizumab 
(0.1 ml) under aseptic conditions. Of these 11 patients six were males and five were 
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females.  The age distribution ranged between 45 to 70 years (mean age 56.27 ± 8.5 
years). Two patients had both DM and HTN, whereas one patient had both DM and 
IHD.  
 
 Details about the pre-treatment and post-treatment BCVA and macular 
thickness values in each individual eye in this group are shown in Figs 10 a and 12a 
and Figs. 10 b and 12 b, respectively.  The mean BCVA at presentation was 
0.127(approximately 6/60) ± 0.08 decimals,  which was not significantly different 
from the post-bevacizumab injection BCVA value of 0.146 (approximately 6/36) ± 
0.07 decimals (`t test [d.f.= 34] = 0.95; P= 0.34). However, there was a significant 
difference (`t’ test [d.f. = 34] = 6.76; P= 0.001) between the  mean macular thickness at 
presentation (469.17 ± 89.67 µ) and the mean macular thickness (310.78 ± 85.61) µ 
after the intravitreal injection of bevacizumab. One eye showed a decreased BCVA 
(from 6/60 to 3/60) following intravitreal bevacizumab; however, the same eye 
exhibited a reduction in macular thickness (from 417µ to 313µ) following the injection. 
Eight eyes did not exhibit any change in visual acuity, but showed a significant 
reduction in macular thickness 
 
Comparisons were made between the three groups at several levels, namely: 
a) Age: Differences between the three groups in the mean ages of the patients in the 
groups were analysed by one-way analysis of variance (ANOVA); the differences were 
not statistically significant (Fisher `f’ value= 0.614; P= 0.546). 
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b) Gender: Males accounted for 20 % of patients in Group 1, 36 % of patients in 
Group 2 and 55 % of patients in group 3; these differences were not statistically 
significant (chi-square  (d.f.=2)=2.7; P> 0.05).  
c) Pre-intervention mean visual acuity: Differences between the groups in the pre-
intervention mean visual acuity were analysed by one-way ANOVA; the differences 
were statistically significant (Fisher `f’ value= 11.018; P= 0.000). Post-hoc testing 
(Tukey’s method) revealed statistically significant differences between the values in 
Group 1 vs. Group 2, Group 1 vs. Group 3 and Group 2 vs. Group 3.  
d) Post-intervention mean visual acuity: Differences between the groups in the post-
intervention mean visual acuity were analysed by one-way ANOVA; the differences 
were statistically significant (Fisher `f’ value= 10.329; P= 0.000). Post-hoc testing 
(Tukey’s method) revealed statistically significant differences between the mean values 
in Group 1 vs. Group 3 and Group 2 vs. Group 3; however, the difference between the 
mean values in Group 1 and Group 2 were not statistically significant.  
e) Pre-intervention mean macular thickness: Differences between the groups in the 
pre-intervention mean macular thickness were analysed by one-way ANOVA; the 
differences were statistically significant (Fisher `f’ value= 112.4; P= 0.000). Post-hoc 
testing (Tukey’s method) revealed statistically significant  differences between the 
mean values in Group 1 vs. Group 2, Group 1 vs. Group 3 and Group 2 vs. Group 3. 
e) Post-intervention mean macular thickness: Differences between the groups in the 
post-intervention mean macular thickness were analysed by one-way ANOVA; the 
differences were statistically significant (Fisher `f’ value= 18.753; P= 0.000). Post-hoc 
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testing (Tukey’s method) revealed statistically significant  differences between the 
mean values in Group 1 vs. Group 2, Group 1 vs. Group 3 and Group 2 vs. Group 3. 
 Although Group 1 did not differ significantly from Groups 2 and 3 in the mean 
age of the patients, there was a definite preponderance of female patients in group 1, 
which was similar to the pattern in Group 2 but different from the pattern in Group 3 
which showed a preponderance of male patients. However, in the 30 eyes of 15 patients 
who suffered from PFT alone, the pre-intervention and post-intervention mean visual 
acuities and the pre-intervention and post-intervention macular thickness values were 
all significantly better than the values noted in the 22 eyes of 14 patients with PFT and 
CME which received intravitreal bevacizumab. Similarly, in the 30 eyes of 15 patients 
who suffered from PFT alone, the pre-intervention mean visual acuity and the pre-
intervention and post-intervention macular thickness values were all significantly better 
than the values noted in the 18 eyes of 11 patients with PFT and CNVM which 
received intravitreal bevacizumab; however, there was no significant difference 
between the post-intervention mean visual acuity in the eyes of these 2 groups of 
patients. 
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TABLE 1 
AGE CATEGEORIES OF THE 40 PATIENTS WHO PRESENTED 
WITH PARAFOVEAL TELANGIECTASIA 
 
Age group 
(Years) 
No. of patients Percentage (%) 
40 – 50 15 37.5 % 
51 – 60 14 35 % 
61 – 70 11 27.5 % 
Total 40 100 
 
MEAN AGE: 54.16 ± 15 YEARS (RANGE =40 YEARS TO 70 
YEARS) MEDIAN: 55 YEARS 
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TABLE 2 
ASSOCIATED SYSTIMIC DISEASES IN THE 40 PATIENTS WHO 
PRESENTED WITH PARAFOVEAL TELANGIECTASIA 
 
 
 
 
 
 
 
 
 
 
 
ASSOCIATED DISEASES NUMBER OF PATIENTS AFFECTED 
HYPERTENSION 13 
DIABETES MELLITUS 20 
ISCHEMIC HEART DISEASES 1 
BRONCHIAL ASTHMA 1 
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FIGURE 7 
ASSOCIATED SYSTIMIC DISEASES IN THE 40 PATIENTS WHO 
PRESENTED WITH PARAFOVEAL TELANGIECTASIA 
 
 
 
 
 
 
 
 
 
 
Associated Systemic Illness
Hypertesion -13
Diabetes mellitus -20
Ischemic Heart Disease -1
Bronchial Asthma - 1
P a g e  | 32 
 
 
 FIGURE 8 
COMPARISON OF PRE-TREATMENT AND POST-TREATMENT 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 30 EYES OF PARAFOVEAL TELANGIECTASIA ONLY 
 
a) BEST CORRECTED VISUAL ACUITY (decimals) 
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 FIGURE 8 
COMPARISON OF PRE-TREATMENT AND POST-TREATMENT 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 30 EYES OF PARAFOVEAL TELANGIECTASIA ONLY 
 
b) MACULAR THICKNESS (µ) 
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FIGURE 9 
COMPARISON OF THE PRE-INJECTION AND POST-
INJECTION 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 22 EYES OF PARAFOVEAL TELANGIECTASIA WITH 
CYSTOID MACULAR EDEMA 
 
a) BEST CORRECTED VISUAL ACUITY (decimals) 
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FIGURE 9 
COMPARISON OF THE PRE-INJECTION AND POST-
INJECTION 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 22 EYES OF PARAFOVEAL TELANGIECTASIA WITH 
CYSTOID MACULAR EDEMA 
 
b) MACULAR THICKNESS (µ) 
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FIGURE 10 
COMPARISON OF THE PRE-INJECTION AND POST-
INJECTION 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 18 EYES OF PARAFOVEAL TELANGIECTASIA WITH 
CHOROIDAL NEOVASCULAR MEMBERANE 
 
a) BEST CORRECTED VISUAL ACUITY (decimals) 
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FIGURE 10 
COMPARISON OF THE PRE-INJECTION AND POST-
INJECTION 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 18 EYES OF PARAFOVEAL TELANGIECTASIA WITH 
CHOROIDAL NEOVASCULAR MEMBERANE 
 
b) MACULAR THICKNESS (µ) 
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FIGURE 11 
COMPARISON OF THE PRE-INJECTION AND POST-
INJECTION 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 22 EYES OF PARAFOVEAL TELANGIECTASIA WITH 
CYSTOID MACULAR EDEMA 
 
a) BEST CORRECTED VISUAL ACUITY (decimals) 
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FIGURE 11 
COMPARISON OF THE PRE-INJECTION AND POST-
INJECTION 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 22 EYES OF PARAFOVEAL TELANGIECTASIA WITH 
CYSTOID MACULAR EDEMA 
 
b) MACULAR THICKNESS (µ) 
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FIGURE 12 
COMPARISON OF THE PRE-INJECTION AND POST-
INJECTION 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 18 EYES OF PARAFOVEAL TELANGIECTASIA WITH 
CHOROIDAL NEOVASCULAR MEMBERANE 
a) BEST CORRECTED VISUAL ACUITY (decimals) 
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FIGURE 12 
COMPARISON OF THE PRE-INJECTION AND POST-
INJECTION 
 
a) BEST CORRECTED VISUAL ACUITY AND 
b) MACULAR THICKNESS 
IN 18 EYES OF PARAFOVEAL TELANGIECTASIA WITH 
CHOROIDAL NEOVASCULAR MEMBERANE 
 
b) MACULAR THICKNESS (µ) 
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 TABLE 3 
Comparison of mean age, pre-intervention and post-intervention best 
corrected visual acuity and pre-intervention and post-intervention 
macular thickness in patients and eyes with parafoveal telangiectasis  
Parameter Group 1 Group 2 Group 3 
Age 52.73±9.05 
(15 patients) 
53.5±7.18 
(14 patients) 
56.27±8.50 
(11 patients) 
Pre-intervention 
Visual acuity 
0.264±0.14 
(30 eyes) 
0.193±0.1 
(22 eyes) 
0.127±0.08 
(18 eyes) 
Post-intervention  
Visual acuity 
(decimals) 
0.264±0.14 
(30 eyes) 
0.256±0.096 
(22 eyes) 
0.146±0.07 
(18 eyes) 
Pre-intervention 
Macular thickness  (µ) 
205.8±56.32 
(30 eyes) 
360.73±43.32 
(22 eyes) 
469.17±89.67 
(18 eyes) 
Post- intervention  
Macular thickness (µ) 
205.8±56.32 
(30 eyes) 
253.45±42.6 
(22 eyes) 
310.78±85.61 
(18 eyes) 
 
Group 1: 30 eyes with parafoveal telangiectasis only 
Group 2: 22 eyes with parafoveal telangiectasis and cystoid macular  
 edema 
Group 3: 18 eyes with parafoveal telangiectasis and choroidal  
 neovascular membrane 
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Statistical analysis of differences between the 3 groups of patients/eyes  
1. Age.  One way analysis of variance (ANOVA); Fisher `f’ value= 0.614;  P= 
0.546 (not significant). 
 
2.  Pre intervention best corrected visual acuity (BCVA).  
a)  One way ANOVA; Fischer ‘f’ value=11.018; P=0.000 (significant) 
b)  Post hoc testing (Tukey’s). Group I vs II;q=11.186;P<0.001(significant) 
   Group I  vs  III;q=5.8;P<0.01(significant) 
   Group II vs  III;q=-5.38;P<0.01(significant)  
 
3.  Post intervention BCVA :  
a)  One way ANOVA; Fischer ‘f’ value=10.329; P=0.000(significant) 
b)  Post- hoc testing (Tukey’s). Group I vs II;q=0.653;P>0.05(not significant) 
  Group I vs  III; q=9.363;P<0.001(significant)  
  Group II vs III;q=8.98;P<0.001(significant) 
 
4.  Pre intervention macular thickness. 
a)  One way ANOVA; Fischer ‘f’ value=112.4; P=0.000 
b)  Post hoc testing (Tukey’s). Group I vs II; q=20.6; P<0.0001 
   Group I vs III; q=35.0;P<0.0001 
   Group II vs III;q=14.42;P<0.001 
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5.  Post intervention macular thickness. 
a)  One way ANOVA; Fischer ‘f’ value=18.753; P=0.000 
b)  Post hoc testing (Tukey’s). Group I vs II;q=6.53;P<0.01 
   Group I vs III;q=14.38;P<0.001 
   Group II vs III;q=7.85;P<0.01 
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FIGURE 15 
OCT APPEARANCE OF PARAFOVEAL TELANGIECTASIA 
WITH CYSTIOD MACULAR EDEMA BEFORE TREATMENT 
 
 
 
FIGURE 16 
OCT APPEARANCE OF PARAFOVEAL TELANGIECTASIA 
WITH CYSTIOD MACULAR EDEMA AFTER TREATMENT 
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FIGURE 17 
OCT APPEARANCE OF PARAFOVEAL TELANGIECTASIA 
WITH CHOROIDAL NEOVASCULAR MEMBERANE BEFORE 
TREATMENT 
 
 
 
FIGURE 18 
OCT APPEARANCE OF PARAFOVEAL TELANGIECTASIA 
WITH CHOROIDAL NEOVASCULAR MEMBERANE AFTER 
TREATMENT 
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DISCUSSION 
 
 Type 2 parafoveal telangiectasia is the most common type of parafoveal 
telangiectasia.  It is acquired, not congenital. Affected patients are middle-aged or older 
(mean 55 years). Males and females are affected equally. This disorder is bilateral, but 
may be asymmetric appearing as unilateral in its early stages. Similarly, patients may 
have visual loss in only one eye. 
 
 The natural course of Idiopathic juxta foveal telangiectasia (IJFT) II has been 
subdivided by Gass and Blodi into five stages. 
 
Three key and distinguishing features of IJFT II are: 
1. The absence of prominent aneurysms or haemorrhage; 
2. The absence of cystic macular edema (CME) or lipid exudation (unless 
Subretinal neovascularisation (SRNV) has developed). The loss of retinal 
transparency and fluorescein staining are primarily caused by intracellular 
edema (contrary to the extracellular fluid causing CME and lipid exudation in 
IJFT I); and 
3. The presence of foveolar atrophy, best seen with OCT, which can simulate a 
lamellar macular hole. Foveal atrophy is the primary cause of the slow 
progressive visual loss occurring over years in these patients (to 20/200 or 
worse), and is distinguishable from the rapid and severe visual loss that may 
occur with the advent of SRNV and fibrosis. 
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 The following OCT features have been described in Type 2 Parafoveal 
telangiectasia 
1. Retinal thickness is variable and does not correlate with the degree of leakage 
seen on FA.46,47,49–52 Central foveolar thickening is consistently absent,47 and 
intraretinal edema is either absent6 or minimal,3,7,47,49–52 superimposed on a 
fovea of normal or reduced thickness.47,53–54 
2. Thinning and disruption of the photoreceptor layer, more readily visualized by 
ultra-high-resolution OCT, is common,7,47,48 confirming that foveal atrophy is 
the primary cause for reduced vision. This disruption was found to correlate 
with VA in 63% of eyes7 and increased with advancing disease.47,48 This finding 
may be of importance in guiding treatment decisions. 
3. Cyst-like structures in the foveola and inner retinal layers are very common 
(50–100% of eyes with Stage 3 or higher. 3,6,7,47–49,51,52 They are referred to as 
“cystoids,” have variable size and are not seen clinically or on FA.48 Because of 
the consistent absence of associated cystoid macular edema6,47 or petaloid 
pooling on FA, these cysts are unlikely a result of exudation, but rather a 
progressive retinal tissue loss.6,47,49 At the foveola, the inner lamellar cyst 
appears as a loss of tissue3,7 with the internal limiting membrane (ILM) 
spanning across it and draping over it.7 This unique feature, the ILM drape, may 
be specific to IJFT IIA.7 This feature is what was previously described as a 
lamellar retinal hole by Gass who did not have the advantage of OCT 
imaging.2,5 Full-thickness macular holes are uncommon in IJFT IIA but have 
been reported.55,56 In most eyes with cysts VA is decreased (20/40 to 20/70),6 
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and cyst enlargement has been reported with disease progression and more 
pronounced visual loss.3,6 
4. Blunting of the foveal pit is common to all stages.48 Foveal flattening or 
thinning is encountered with more advanced disease.6 
5. Intraretinal neovascularization near the foveola, seen as highly reflective dots in 
the inner and outer nuclear layers48 is found in 21% of eyes.7 
6. Central intraretinal hyper-reflective lesions that cause nonspecific posterior 
shadowing and correspond to hyperpigmented RPE plaques are observed.3,5,57 
The crystalline deposits are generally too small to induce photoreflectance.3 
 
 When considering treatment, the therapeutic attempts for nonproliferative IJFT 
II, and treatment modalities for the SRNV of the proliferative stage must be 
distinguished. 
 
 The angiographic late intraretinal staining pattern in IJFT IIA has prompted 
many ophthalmologists to interpret it as macular edema secondary to retinal vascular 
leakage. Several treatment modalities have been tried to treat this “macular edema.” 
 
 To start, argon laser photocoagulation (ALPC) is not effective in the treatment 
of nonproliferative IJFT IIA.3, 11. Gass and Blodi noted that the long-term prognosis for 
patients with IJFT IIA is poor and laser treatment resulted in either worsened or no 
change in VA. Gass did not recommend ALPC in nonproliferative IJFT. Park et al. 3, 
also found no improvement or stabilization of vision with grid ALPC.  
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 Verteporfin photodynamic therapy (PDT) has also been tried in patients with 
nonproliferative IJFT II in an attempt to reduce the permeability of the telangiectatic 
vessels.58 However, PDT improved neither vision nor the macular edema and appeared 
therefore not effective. No adverse effects were reported. 
 
 Preliminary case reports (five cases) of Intravitreal triamcinolone acetate( 
IVTA) in nonproliferative IJFT II suggested an effect, with mild improvement of visual 
acuity, but the follow-up was very short59–61. The retrospective study of 19 eyes by Wu 
et al., however, showed that IVTA, at a dose of 4 mg, does not improve VA in most 
eyes with nonproliferative IJFT I162. IVTA is likely to have a minor, or no, therapeutic 
effect in nonproliferative IJFT IIA, which, coupled with a high incidence of cataract 
and increased intraocular pressure, suggest that it should be avoided as treatment of this 
condition. 
 
 Recent publications on intravitreal anti-VEGF injections, namely bevacizumab, 
report on possible short-term VA increase in some cases of IJFT II 63, 64. In one case, 
with initial VA 20/50, treated with an intravitreal injection of bevacizumab (1.25 mg), 
VA improved but macular edema recurred after 3 months, requiring a repeat injection 
with no significant improvement of VA thereafter.64. Another retrospective series of 
seven eyes treated with two doses of intravitreal bevacizumab (1.5 mg) at 4-week 
intervals demonstrated a short-term decrease in retinal thickness and a reduction in 
angiographic leakage63. When these same patients received further injections, 
depending on disease activity, and were followed for approximately 18 months, it was 
noted that mean VA had increased, central retinal thickness had decreased following 
each treatment, but treatment effect appeared less pronounced with subsequent 
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injections, and rebound effect recurred earlier than it had after the initial two injections. 
At the last visit, retinal thickness had increased in selected retinal sectors including the 
fellow eye. The authors concluded that intravitreal bevacizumab for nonproliferative 
IJFT II has only a transient effect. They believed that VEGF plays a pathophysiological 
role in IJFT II, because, in their opinion, the structural capillary changes described 
histopathologically lead to a disturbed exchange of oxygen and substrates between the 
vascular lumen and neurosensory retina, which in turn may lead to a hypoxia-induced 
increased VEGF release by retinal cells.  
 
 However, in another two patients with nonproliferative IJFT IIA treated with 
intravitreal bevacizumab (1.25 mg) and followed for 12 months, leakage on FA 
decreased likewise, underlining the effect of bevacizumab on vessel stability and 
permeability, but this was not accompanied by an increase in VA despite triple 
injections.66 Furthermore, small cystic changes seen on OCT remained unchanged, 
emphasizing that visual deterioration is caused by microcystic degeneration and 
progressive retinal atrophy and not by intraretinal edema, and therefore cannot be 
halted with intravitreal anti-VEGF injections. A more recent and larger retrospective 
review of nine eyes treated with intravitreal bevacizumab and followed from 4 to 27 
months, corroborated that intravitreal bevacizumab decreased FA leakage but had no 
short-term effect on VA or OCT appearance.67 Similar results to these two reports were 
observed with intravitreal injections of pegaptanib.68 These three studies suggest that 
eyes with minimal cystic changes on OCT do not show functional improvement despite 
repeated intravitreal anti-VEGF injections,66,68 and that there seems to be no apparent 
visual acuity or OCT benefit to using intravitreal anti-VEGF in the absence of 
SRNV.66,67  Moreover, it has been suggested that VEGF plays a role in photoreceptor 
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differentiation, may contribute to photoreceptor survival, and may serve a role in 
maintaining retinal vascular homeostasis.69Therefore, it cannot be ruled out that 
blocking VEGF may cause an acceleration of apoptosis among ganglion cells and 
photoreceptors in IJFT IIA.65  This remains to be tested. 
 
 The natural history of untreated SRNV in IJFT II is generally poor with 80% of 
eyes in a series of 26 eyes having a final VA of 20/200 or worse. Before the advent of 
VEGF antagonists, therapeutic options for SRNV associated with IJFT II included laser 
photocoagulation, PDT with or without IVTA, transpupillary thermotherapy (TTT), 
and surgical removal of the SRNV.  
 
 Matsumoto et al. 36 investigated the efficacy of intravitreal bevacizumab for the 
treatment of idiopathic macular telangiectasia (IMT). All the ten eyes of eight patients 
were treated with intravitreal bevacizumab (1.25 mg) injections at baseline. There were 
no changes in the mean visual acuity in either eye in any of the patients. These authors 
concluded that Type 2 IMT improved anatomically with bevacizumab treatment, 
despite a lack of improvement in vision, and   bevacizumab effectively decreased 
vascular permeability and retinal edema in the short term. In the present investigation 
(dissertation), it was found that best corrected visual acuity improved for at least one 
line and showed significant reduction in macular thickness.  
 
 Gamulescu et al.37 described functional and morphological long-term follow-up 
results in patients with IMT treated with intravitreal bevacizumab in three consecutive 
male patients with IMT who were treated with intravitreal bevacizumab injections. A 
single intravitreal bevacizumab injection resulted in a marked improvement in best 
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corrected visual acuity (BCVA) from 20/50 to 20/20 than the patient with type 1 
(aneurysmal) IMT during the first 4 weeks. The patients with type 1 IMT with 
pronounced macular oedema on OCT may benefit from intravitreal bevacizumab 
injections, showing functional as well as morphological improvement, while patients 
with type 2 IMT with minimal cystic changes on OCT do not show functional 
improvement despite repeated injections. The present investigation also showed the 
same outcome after intravitreal bevacizumab injection. 
 
 Issa et al.38 reported on the short-term effects of intravitreal bevacizumab in 
patients with type 2 IMT in a noncomparative, interventional, retrospective case series 
in seven eyes of six patients with type 2 IMT. Patients received 2 doses of intravitreal 
bevacizumab (1.5 mg) at a 4-week interval. A significant increase in mean VA of 8 
ETDRS letters at 8 weeks was found. Visual acuity improved by more than 15 letters in 
one patient and by 10 to 15 letters in two patients and remained stable (to +10 letters) in 
another four patients, compared with baseline. In OCT imaging, mean retinal thickness 
showed a significant reduction in the foveal and in the parafoveal zones. The most 
pronounced effect (mean decrease, 22I¼m) was in the parafoveal temporal zone. No 
significant ocular or systemic side effects, were observed. These authors concluded, 
based on their short-term results, that inhibition of vascular endothelial growth factor 
(VEGF) by intravitreal bevacizumab is associated with a decrease in retinal thickness 
and a reduction in angiographic leakage in type 2 IMT; they also opined that 
intravitreal bevacizumab may improve VA in affected patients. 
 
 Kovach et al.39 sought to determine whether inhibition of VEGF-A affects 
visual acuity, fluorescein angiographic, and OCT outcomes in patients with perifoveal 
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telangiectasia (PT) (also synonyms are  macular telangiectasia, Type 2 juxtafoveolar 
retinal telangiectasis group 2A). In this retrospective review of patients with PT treated 
with intravitreal bevacizumab at the Bascom Palmer Eye Institute, in Florida (USA), 
best-corrected visual acuity, fluorescein angiography, and OCT measurements were 
performed on nine eyes of eight patients. Five eyes had proliferative PT, characterized 
by subretinal neovascularization involving the macula. After treatment (follow-up 
ranged from 4 to 27 months) the mean BCVA remained stable for the four eyes with 
nonproliferative PT, whereas in the five eyes with proliferative PT, BCVA was 
unchanged or improved after treatment. All eyes demonstrated decreased intraretinal 
leakage on fluorescein angiography after an injection of bevacizumab, and eyes with 
proliferative PT showed decreased growth and leakage of the subretinal 
neovascularization. The mean decrease in OCT central retinal thickness was less than 
30 μ. These investigators were of the opinion that in nonproliferative PT, intravitreal 
bevacizumab decreases fluorescein angiographic leakage without any short-term effect 
on visual acuity or OCT appearance whereas in proliferative PT, intravitreal 
bevacizumab arrests the leakage and growth of subretinal neovascularization with the 
possibility of visual acuity improvement. 
 
 Moon et al.40 assessed the potential visual benefit of intravitreal bevacizumab in 
a patient with idiopathic juxtafoveal retinal telangiectasis refractory to focal laser 
treatment; an intravitreal injection of bevacizumab (1.25 mg) was given. Within 1 
week, visual acuity improved from 20/50 to 20/25 and OCT demonstrated complete 
resolution of macular edema without any adverse effect due to the injection. The 
macular edema recurred after 3 months, requiring a repeat injection of bevacizumab, 
with subsequent resolution of macular edema. These authors believed that an 
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intravitreal injection of bevacizumab may provide potential short-term visual benefit in 
patients with macular edema from idiopathic juxtafoveal retinal telangiectasis. 
 
 Idiopathic perifoveal telangiectasia (IPT) is a disorder characterized by focal 
parafoveal capillary dilatation of unknown cause. Photodynamic therapy (PDT) is 
reported to be efficacious in the treatment of subretinal neovascularization (SRN) 
associated with idiopathic juxtafoveal retinal telangiectasis; however, visual 
improvement is limited. Cakir et al.41 described the clinical, angiographic, and OCT 
findings for a patient with IPT complicated by SRN who underwent treatment with 
PDT and bevacizumab. The patient underwent two sessions of PDT; however, 
metamorphopsia persisted, and visual acuity further decreased to 20/100 after the 
second PDT. Hence, after PDT, two injections of intravitreal bevacizumab (1.25 mg) 
were administered, following which visual acuity increased dramatically from 20/100 
to 20/25. Four months after the second injection, there was no recurrence, and the 
patient was asymptomatic. These authors concluded that intravitreal bevacizumab 
treatment should be considered for patients with SRN associated with perifoveal 
telangiectasis, especially after insufficient therapeutic response to PDT. 
  
 Mandal et al.42, in a nonrandomised interventional case series, evaluated the 
efficacy and safety of intravitreal bevacizumab in the treatment of SRN secondary to 
type 2A idiopathic juxtafoveal telangiectasia (IJT). Intravitreal bevacizumab (1.25 
mg/0.05 ml) was injected as primary treatment into six eyes of six patients with SRN 
due to IJT. OCT and fundus fluorescein angiography (FFA) findings were examined 
before and after treatment (the patients were followed up for 3-6 months). Pre-injection 
BCVA measured from 20/400 to 20/120 (mean 20/200). After a mean follow-up of 4.2 
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months, post-injection BCVA measured from 20/200 to 20/50 (mean 20/100). At the 
last visit, BCVA was found to have improved by two or more lines in five eyes (83%) 
and remained the same in one eye (17%). The mean central foveal thickness improved 
from 263 mm (range, 165 to 393 mm) to 201 mm (range, 126 to 351 mm), representing 
an average reduction of 62 . Only one eye received more than one two bevacizumab 
injections and no significant complications were observed. These authors concluded 
that in their small series, intravitreal bevacizumab appeared to be a safe and effective 
treatment for SRN secondary to type 2A IJT. 
 
 Charbel et al.43 evaluated, retrospectively, the effects of intravitreal 
bevacizumab for non-proliferative type 2 idiopathic macular telangiectasia (type 2 
IMT) for a mean follow-up for 18 months. Six eyes of five patients with type 2 IMT 
received two doses of intravitreal bevacizumab (1.5mg) at a 4 week interval. The mean 
VA increased significantly, Parafoveal leakage in FFA and mean central retinal 
thickness was decreased in all eyes following treatment. A rebound effect was observed 
after 3-4 months, and at the last visit, retinal thickness was increased in selected retinal 
sectors including the fellow eye. Inhibition of vascular endothelial growth factor 
(VEGF) by intravitreal bevacizumab may lead to functional improvement as well as 
transient decrease in leakage and retinal thickness in patients with type 2 IMT. 
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SUMMARY 
 
 The term “retinal telangiectasis” has been used to describe congenital vascular 
anomalies in retinal blood vessels, resulting in localised, abnormal vessel segments that 
exhibit leakage. Parafoveal telangiectasis (PFT) refers to telangiectasis that is localised 
to the capillaries of the parafoveal region, and is characterized by microaneurysmal and 
saccular dilation and capillary nonperfusion of the parafoveal capillaries. While many 
previous studies have documented clinical presentation and angiographic features, there 
have been fewer studies on imaging and management of the condition. The aims of the 
present investigation were to document the clinical features, fundus fluorescein 
angiographic (FFA) and optical coherence tomographic (OCT) findings, and to 
evaluate the efficacy of intravitreal bevacizumab in treatment, in patients presenting 
with type 2  parafoveal telangiectasis at a tertiary eye care facility in southern India.  
 
 Forty patients (80 eyes) were enrolled in this investigation, fourteen of whom 
were males and twenty-six of whom were females. The patients ranged in age from 40 
to 70 years (mean [± standard deviation] age: 54.16 [±15] years). Fifteen patients were 
between 40 to 50 years of age, 14 patients were between 51 to 60 years of age and 
eleven patients were between 61 to 70 years of age.  
 
 All forty patients enrolled in the study suffered from bilateral parafoveal 
telangiectasis. These were divided into three groups: 
a) Group 1, which included 15 patients with PFT who were under observation and 
treated conservatively; three were males and 12 were females, ranging in age 
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from 40 to 69 years (mean age 52.73 ± 9.05 years). Five patients had diabetes 
mellitus and hypertension as associated systemic illnesses, one patient had both 
DM and ischemic heart disease (IHD) and five patients had only DM. In the 30 
eyes in this group of 15 patients, the mean vision at presentation was 0.264 ± 
0.14 decimals, which was exactly the same as the mean vision (0.264 ± 0.14 
decimals) after the three month follow -up period. In the 30 eyes in this group 
of 15 patients, the mean macular thickness at presentation (as measured by 
OCT) was 205.8 ± 56.32 µ, which was exactly the same as the mean macular 
thickness (205.8 ± 56.32 µ) after the three month follow- up period. 
b)  Group 2 included 14 patients with PFT complicated by cystoid macular oedema 
(CME), who were treated with intravitreal injections of bevacizumab (each 
0.1ml) under aseptic conditions.  Five of the fourteen patients were males and 
nine were females; the patients ranged in age from 40 to 65 years (mean age 
53.5 ± 7.18 years). Four patients had DM and HTN as associated systemic 
illnesses, two patients had only HTN, two patients had only DM and one patient 
had bronchial asthma. In the 22 eyes which received an intravitreal injection of 
bevacizumab in this group of 14 patients, the mean vision at presentation was 
0.19 (approximately 6/18) ± 0.1 decimals, which significantly improved to 
0.256 (6/12) ± 0.096 following the injection of bevacizumab (`t’ test (degree of 
freedom [d.f. =42] = 2.13; P= 0.04). In the 22 eyes which received an 
intravitreal injection of bevacizumab in this group of 14 patients,  the mean 
macular thickness at presentation was 360.73 ± 43.22 µ, which showed a 
significant decrease to 253.45 ± 42.6 µ following the injection of bevacizumab 
(`t’ test [d.f.=42]= 8.29; P < 0.0001). None of the eyes showed decreased visual 
P a g e  | 63 
 
acuity after the intravitreal injection. Six eyes did not exhibit any change in 
visual acuity, but exhibited a significant reduction in macular thickness. 
c)  Group 3 included 11 patients with PFT and choroidal neovascular membrane 
(CNVM) who were treated with intravitreal injections of bevacizumab (each 
dose being 0.1 ml) under aseptic conditions; six of the 11 patients were males 
and five were females.  The patients ranged in age from 45 to 70 years, with a 
mean age of 56.27 ± 8.50 years. Two patients had both DM and HTN, whereas 
one patient suffered from both DM and IHD. In the 18 eyes which received an 
intravitreal injection of bevacizumab in this group of 11 patients, the mean 
vision at presentation was 0.13 (approximately 6/60) ± 0.08 decimals, while the 
mean vision after the bevacizumab injection was 0.15 (6/36) ± 0.07; this 
difference was not statistically significant (`t’ test [d.f. =54]= 0.99; P= 0.35). In 
the 18 eyes which received an intravitreal injection of bevacizumab in this 
group of 11 patients,  the mean macular thickness at presentation was 469.17 ± 
89.67 µ , which showed a significant decrease to 310.78 ± 85.61 µ following the 
injection of bevacizumab (`t’ test [d.f.=54]= 6.76; P < 0.0001). One of the 
patients showed a decreased visual acuity from 6/60 to 3/60; however, the 
macular thickness in this eye showed a reduction from 417 µ to 313 µ. Eight 
eyes did not exhibit any changes in visual acuity, but exhibited significant 
reductions in macular thickness. 
 Comparisons were made between the three groups at several levels, namely: 
a)  Age: Differences between the three groups in the mean ages of the patients in 
the groups were analysed by one-way analysis of variance (ANOVA); the differences 
were not statistically significant (Fisher `f’ value= 0.614; P= 0.546). 
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b)  Gender: Males accounted for 20 % of patients in Group 1, 36 % of patients in 
Group 2 and 55 % of patients in group 3; these differences were not statistically 
significant (chi-square  (d.f.=2)=2.7; P> 0.05).  
 
c)  Pre-intervention mean visual acuity: Differences between the groups in the 
pre-intervention mean visual acuity were analysed by one-way ANOVA; the 
differences were statistically significant (Fisher `f’ value= 11.018; P= 0.000). Post-hoc 
testing (Tukey’s method) revealed statistically significant differences between the 
values in Group 1 vs. Group 2, Group 1 vs. Group 3 and Group 2 vs. Group 3.  
 
d)  Post-intervention mean visual acuity: Differences between the groups in the 
post-intervention mean visual acuity were analysed by one-way ANOVA; the 
differences were statistically significant (Fisher `f’ value= 10.329; P= 0.000). Post-hoc 
testing (Tukey’s method) revealed statistically significant differences between the mean 
values in Group 1 vs. Group 3 and Group 2 vs. Group 3; however, the difference 
between the mean values in Group 1 and Group 2 were not statistically significant.  
 
e)  Pre-intervention mean macular thickness: Differences between the groups in 
the pre-intervention mean macular thickness were analysed by one-way ANOVA; the 
differences were statistically significant (Fisher `f’ value= 112.4; P= 0.000). Post-hoc 
testing (Tukey’s method) revealed statistically significant  differences between the 
mean values in Group 1 vs. Group 2, Group 1 vs. Group 3 and Group 2 vs. Group 3. 
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f)  Post-intervention mean macular thickness: Differences between the groups 
in the post-intervention mean macular thickness were analysed by one-way ANOVA; 
the differences were statistically significant (Fisher `f’ value= 18.753; P= 0.000). Post-
hoc testing (Tukey’s method) revealed statistically significant  differences between the 
mean values in Group 1 vs. Group 2, Group 1 vs. Group 3 and Group 2 vs. Group 3. 
 
 Although Group 1 did not differ significantly from Groups 2 and 3 in the mean 
age of the patients, there was a definite preponderance of female patients in group 1, 
which was similar to the pattern in Group 2 but different from the pattern in Group 3 
which showed a preponderance of male patients. However, in the 30 eyes of 15 patients 
who suffered from PFT alone, the pre-intervention and post-intervention mean visual 
acuities and the pre-intervention and post-intervention macular thickness values were 
all significantly better than the values noted in the 28 eyes of 14 patients with PFT and 
CME. Similarly, in the 30 eyes of 15 patients who suffered from PFT alone, the pre-
intervention mean visual acuity and the pre-intervention and post-intervention macular 
thickness values were all significantly better than the values noted in the 22 eyes of 11 
patients with PFT and CNVM; however, there was no significant difference between 
the post-intervention mean visual acuity in the eyes of these 2 groups of patients.  
 
 The results suggest that in patients with parafoveal telangiectasis alone, the 
mean visual acuity and mean macular thickness values are better than the same values 
in patients with parafoveal telangiectasis complicated by cystoid macular oedema or by 
choroidal neovascular membrane; there is neither short-term improvement nor 
deterioration in these parameters when the patients with parafoveal telangiectasis alone 
are managed conservatively. In patients with parafoveal telangiectasis complicated by 
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cystoid macular oedema there is definite short-term improvement in the visual acuity 
and in the macular thickness following intravitreal injection of bevacizumab. In 
patients suffering from parafoveal telangiectasis complicated by choroidal neovascular 
membrane, there is definite short-term improvement in the macular thickness, but not 
in visual acuity, following intravitreal injection of bevacizumab. Further studies of a 
longer duration and on a larger sample size of patients are required to confirm these 
initial results.  
 
  
P a g e  | 67 
 
CONCLUSION 
 
 The results suggest that in patients with parafoveal telangiectasis alone, the 
mean visual acuity and mean macular thickness values are better than the same values 
in patients with parafoveal telangiectasis complicated by cystoid macular oedema or by 
choroidal neovascular membrane; there is neither short-term improvement nor 
deterioration in these parameters when the patients with parafoveal telangiectasis alone 
are managed conservatively. In patients with parafoveal telangiectasis complicated by 
cystoid macular oedema there is definite short-term improvement in the visual acuity 
and in the macular thickness following intravitreal injection of bevacizumab. In 
patients suffering from parafoveal telangiectasis complicated by choroidal neovascular 
membrane, there is definite short-term improvement in the macular thickness , but not 
in visual acuity, following intravitreal injection of bevacizumab. Further studies of a 
longer duration and on a larger sample size of patients are required to confirm these 
initial results.  
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Group: 1/2/3 
 
Name:-    Age:  Sex: 
 
MR No. :- 
 
Address:- 
 
Mobile No.:- 
 
 
Systemic Diseases: - 
    Duration 
Diabetes Mellitus-  
Hypertension- 
IHD- 
Cerebrovascular accident- 
Others - 
 
SCREENING:- 
 
BEST CORRECTED VISUAL ACUITY : 
 
SLIT LAMP EXAMINATION: 
 
 
 
 
 
 
90 D LENS EXAMINATION: 
 
 
 
 
 
INDIRECT OPHTHALMOSCOPY: 
 
 
 
 
OCT EXAMINATION: 
 
 
 
 
 
 
F F A EXAMINATION: 
 
 
 
 
 
INTERVENTION: 
 
 
 
 
 
FOLLOW UP: 
Date Visual acuity OCT Fundus Remarks 
     
     
 
Name Age Sex No Sys illness RE LE RE OCT- pre LE OCT- pre RE post LE post RE OCT post LE OCT post
Saghayamary.D 45 F P747271 DM,IHD  6/60  6/60 253 253  6/60  6/60 253 253
Pushpam.N 59 F P743515 None  6/24P  6/36P 231 221  6/24P  6/36P 231 221
Masilamani 55 F P715262 None  6/36  6/18 156 196  6/36  6/18 156 196
Maheswari.V 47 F P697895 DM,HTN  6/60  6/60 138 133  6/60  6/60 138 133
Kulandai Theresa.S 42 F P695305 DM  6/12  6/9 202 195  6/12  6/9 202 195
Hamdunisa.S 62 F P609727 DM,HTN  6/60  6/36 214 165  6/60  6/36 214 165
Chitra.J 43 F P541652 DM  6/18  6/24 196 196  6/18  6/24 196 196
Rajeswari.B 50 F P730418 DM,HTN  6/36  6/12 185 185  6/36  6/12 185 185
Malliha.V 52 F P761085 DM,HTN  6/18  6/18 301 255  6/18  6/18 301 255
Saravanan.S 48 M P761091 DM  6/60  6/18 265 265  6/60  6/18 265 265
Pappa.S 60 F P768045 DM  6/24  6/24 322 281  6/24  6/24 322 281
Padmavathy 40 F P602027 None  6/18  6/12P 256 256  6/18  6/12P 256 256
Sivaramakrishnan.R 69 M P591981 DM,HTN  6/18  6/36 138 118  6/18  6/36 138 118
Indrani.K 67 F P608899 DM  6/18  6/60 158 101  6/18  6/60 158 101
Velayutham.P 52 M P542027 None  6/24  6/18 183 156  6/24  6/18 183 156
Only PFT
Name Age Sex No Sys illness RE LE Laterality RE OCT- pre LE OCT- pre RE Avastin doses LE Avastin doses RE post LE post RE OCT post LE OCT post
Rajmohamad.M 52 M P654296 None  5/60  6/60 B/L 353 398 1 1 6/60 6/36 233 308
Selvarangam.V 65 M P660465 DM,HTN  6/60  6/60 B/L 411 352 1 1 6/24 6/24 256 225
Rajammal.G 50 F P748932 Asthma  6/12 6/6 U/L 299 158 1 0 6/12 6/6 239 155
Valarmathi.R 47 F P663156 None  5/60 6/36 B/L 389 330 1 1 6/24 6/36 265 303
Sundari.G 40 F P645825 None 6/36  6/9 U/L 410 212 1 0 3/60 6/9 298 212
Vijayalakshmi S.S 61 F P708140 HTN  6/36  6/36 B/L 336 352 1 1 6/24 6/24 209 241
Vasantha.A 53 F P699494 DM,HTN  6/24  6/18p U/L 350 255 1 0 6/36 6/18 298 255
Maruthambal.G 56 F P746873 DM,HTN  6/60 6/18 U/L 411 209 1 0 6/18 6/18 340 209
Haridoss.S 54 M P792192 HTN  6/24  6/18 B/L 333 313 1 1 6/18 6/18 262 221
Abdul malik.A 60 M P795477 DM  6/24  6/60 B/L 412 356 1 1 6/24 6/24 310 201
Manjula.S 54 F P816527 DM,HTN  6/9 6/24 U/L 131 302 0 1 6/9 6/18 131 198
Hassan.S 50 M P819258 None  6/36  6/18 B/L 399 316 1 1 6/18 6/18 288 215
Indra.K 44 F P827018 DM 6/60 6/12 U/L 455 212 1 0 6/36 6/12 255 212
Pushpavalli.A 63 F P815556 None  6/24  6/24 B/L 344 315 1 1 6/24 6/18 199 212
PFT with CME
Name Age Sex No Sys illness RE LE Laterality RE OCT- pre LE OCT- pre RE Avastin doses LE Avastin doses RE post LE post RE OCT post LE OCT post
Sathia kumari.A 54 F P831789 DM,HTN 6/60 3/60 B/L 622 556 3 3 6/36 6/60 533 452
Vadivel.A 46 M P832732 None 6/36 6/60 B/L 451 402 3 3 6/36 6/60 301 302
Kandhasamy.K.R 65 M P840708 DM,HTN 6/60 6/60 B/L 453 356 3 3 6/60 6/60 256 266
Noor mohamed.S 63 M P775061 None 6/12 6/60 U/L 212 417 0 4 6/12 3/60 212 313
Raghavendra rao.C.V 61 F P825963 DM,IHD 3/60 6/18 U/L 356 229 3 0 6/60 6/18 212 240
Selvaraj.N 63 M P780216 None 6/36 6/24 B/L 400 521 3 4 6/36 6/24 317 301
Bhaskar.R 45 M P775756 None 6/24 3/60 B/L 399 454 3 3 6/24 6/60 244 256
Elangovan.S 53 M P761330 None 3/60 6/12 U/L 432 122 5 0 6/24 6/12 232 256
Fathima rojali 51 F P763922 None 6/60 6/18 U/L 441 130 3 0 6/60 6/18 201 131
Rajalakshmi.B 70 F P767084 None 6/60 6/24 B/L 621 398 3 5 6/36 6/24 400 288
Nadiyammal.G 48 F P841243 None 3/60 6/36 B/L 625 541 3 3 6/60 6/36 384 336
PFT with CNVM
